Table 19. [Effect of Fibrates on Statin Pharmacokinetics ()]. - Endotext

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

Endotext [Internet].

Show details

Table 19.

Effect of Fibrates on Statin Pharmacokinetics (215,235,236)

Statin	Gemfibrozil	Fenofibrate
Atorvastatin	Increase in C-Max by 1.5-Fold	No Change
Simvastatin	Increase in C-Max by 2-Fold	No Change
Pravastatin	Increase in C-Max by 2-Fold	No Change
Rosuvastatin	Increase in C-Max by 2-Fold	No Change
Lovastatin	Increase in C-Max by 2.8-Fold	No Change
Pitavastatin	Increase in C-Max by 41%	Unknown
Fluvastatin	No Change	No Change

From: Triglyceride Lowering Drugs

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

Contents

Views

Cite this Page
Feingold KR. Triglyceride Lowering Drugs. [Updated 2024 Jan 18]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Table 19. [Effect of Fibrates on Statin Pharmacokinetics ()].

Related information

PubMed
Links to PubMed

Similar articles in PubMed

Review TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.[Endocr Pract. 2017]
Review TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y, Shapiro MD. Endocr Pract. 2017 Jan; 23(1):100-112. Epub 2016 Nov 7.
Review Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.[J Manag Care Pharm. 2008]
Review Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ, Watson KE, Talbert RL. J Manag Care Pharm. 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1.
Review Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.[Atherosclerosis. 2015]
Review Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Ito MK. Atherosclerosis. 2015 Oct; 242(2):647-56. Epub 2015 Jun 11.
Review Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.[Lipids Health Dis. 2017]
Review Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J, Hurt-Camejo E. Lipids Health Dis. 2017 Aug 10; 16(1):149. Epub 2017 Aug 10.
Review Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.[Am J Ther. 2016]
Review Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S, Arora RR, Singh M, Khosla S. Am J Ther. 2016 May-Jun; 23(3):e905-10.

See reviews...See all...

Recent Activity

Clear Turn Off Turn On

Table 19. [Effect of Fibrates on Statin Pharmacokinetics ()]. - Endotext
Table 19. [Effect of Fibrates on Statin Pharmacokinetics ()]. - Endotext
Mus musculus chromatin modifying protein 2A (Chmp2a), mRNA
Mus musculus chromatin modifying protein 2A (Chmp2a), mRNA
gi|142367036|ref|NM_026885.2|
Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on